ALLMedicine™ IgA Nephropathy Center
Research & Reviews 1,101 results
https://doi.org/10.1007/s11255-021-03063-7 10.1007/s00296-016-3425-3 10.1007/s00467-017-3597-4 10.1007/s11695-017-2940-y
International Urology and Nephrology; Torun Bayram M, Heybeli C et. al.
Dec 1st, 2021 - To compare clinical, pathological, and long-term renal outcomes of children with Henoch-Schonlein purpura nephritis (HSPN) and IgA nephropathy (IgAN). The medical records of patients diagnosed as HSPN and IgAN during childhood were evaluated retro...
https://doi.org/10.1007/s10157-021-02160-2 10.1002/art.1780380213 10.1002/art.27584 10.1053/j.ajkd.2008.12.034 10.1007/s10157-013-0810-z 10.1053/ajkd.2002.31987 10.1159/000093254 10.1136/ard.49.6.363 10.3899/jrheum.111453 10.1097/RHU.0000000000000302 10.1007/s10238-019-00602-6 10.5414/CN109971 10.1080/24725625.2020.1739193 10.2215/CJN.07420716
Clinical and Experimental Nephrology; Sawamura M, Sawa N et. al.
Dec 1st, 2021 - We examined whether advances in treatment strategies from older disease-modifying antirheumatic drugs (DMARDs) to new biologic agents and methotrexate improved renal complications and outcome in patients with rheumatoid arthritis (RA). We reviewed...
https://doi.org/10.1007/s40265-021-01643-6 10.1002/art.37715 10.1056/NEJMoa2023386 10.1371/journal.pone.0164646 10.1681/ASN.2013020143 10.1056/NEJMc2104672 10.1002/acr2.11185 10.1681/ASN.2016111179
Drugs Lee A
Nov 27th, 2021 - Avacopan (TAVNEOS™) is a complement 5a receptor (C5aR) antagonist developed by ChemoCentryx for the treatment of autoimmune diseases including anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. The therapeutic effects of avacop...
BMC Nephrology; Wei SY, Guo S et. al.
Nov 27th, 2021 - IgA nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide, and its diagnosis depends mainly on renal biopsy. However, there is no specific treatment for IgAN. Moreover, its causes and underlying molecular events requir...
International Journal of Immunogenetics; Selvaskandan H, Barratt J et. al.
Nov 26th, 2021 - IgA nephropathy (IgAN) is the most common pattern of primary glomerular disease reported worldwide. Up to 40% of those with IgAN progress to end-stage kidney disease within 20 years of diagnosis, with no currently available disease-specific treatm...
Guidelines 2 results
Kidney International; Rovin BH, Adler SG et. al.
Sep 25th, 2021 - The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Glomerular Diseases is an update to the KDIGO 2012 guideline. The aim is to assist clinicians caring for individuals with glomerulonephritis (G...
Clinical and Experimental Nephrology; Yuzawa Y, Yamamoto R et. al.
Apr 21st, 2016 - Evidence-based clinical practice guidelines for IgA nephropathy 2014.|2016|Yuzawa Y,Yamamoto R,Takahashi K,Katafuchi R,Tomita M,|diagnosis,etiology,therapy,
Clinicaltrials.gov 34 results
Nov 24th, 2021 - The study hypothesis: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a broad spectrum of clinical manifestations. Its mechanisms are not well understood. It is known that its development is influenced by genetic factors an...
Nov 17th, 2021 - This trial is a multicenter, randomized, double-blind, placebo controlled parallel group study. The purpose of the study is to evaluate the efficacy and safety of LNP023 compared to placebo on proteinuria reduction and slowing disease progression ...
Nov 12th, 2021 - The purpose of this study is to evaluate the safety and the tolerability of ADR-001 in Immunoglobulin A (IgA) Nephropathy patients. In addition, the investigators will evaluate the efficacy of ADR-001 for IgA Nephropathy patients.
Oct 25th, 2021 - Approximately 320 patients with biopsy-proven IgAN will be randomized to receive 0.75 mg atrasentan or placebo daily for 132 weeks. Subjects receive a maximally tolerated and stable dose of a RAS (renin-angiotensin system) inhibitor (such as angio...
Oct 19th, 2021 - The purpose of AROC3-1001 is to evaluate the safety, tolerability, pharmacokinetics and/or pharmacodynamics in adult healthy volunteers (HVs) and in adult patients with paroxysmal nocturnal hemoglobinuria (PNH) and adult patients with complement-m...
News 26 results
Nov 10th, 2021 - Daily treatment of patients with IgA nephropathy with an oral glucocorticoid, methylprednisolone, led to significant reductions in the rate of kidney failure and a composite tally of adverse incident renal outcomes in a multicenter, randomized tri...
Jun 9th, 2021 - A first-in-class oral inhibitor of the alternative complement pathway that drives the pathogenesis of primary glomerulonephritis, iptacopan (LNP023, Novartis), is showing early promise as the first targeted therapy for the treatment of IgA nephrop...
May 21st, 2021 - The FDA has announced that it will need more time to review the biologics license application (BLA) for narsoplimab as a potential therapeutic option in patients with hematopoietic stem cell transplant–associated thrombotic microangiopathy (HSCT-T...
Apr 20th, 2021 - Treatment with the sodium-glucose cotransporter-2 (SGLT2) inhibitor dapagliflozin (Farxiga) was safe and effective for slowing progression of chronic kidney disease (CKD) and the development of end-stage renal disease for patients with immunoglobu...
Jan 22nd, 2021 - Severe renal arteriosclerosis was associated with a ninefold increased risk of atherosclerotic cardiovascular disease in patients with lupus nephritis, based on data from an observational study of 189 individuals. Mohammed Haneefa Nizamudeen/Getty.